- Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
- Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
- Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
- Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
- Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
- Pyxis Oncology Announces $50 Million Private Placement
- Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
- Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
- Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
More ▼
Key statistics
On Wednesday, Pyxis Oncology Inc (PYXS:NSQ) closed at 4.40, -35.77% below its 52-week high of 6.85, set on Feb 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.44 |
---|---|
High | 4.70 |
Low | 4.24 |
Bid | 4.21 |
Offer | 4.69 |
Previous close | 4.45 |
Average volume | 415.96k |
---|---|
Shares outstanding | 58.13m |
Free float | 46.22m |
P/E (TTM) | -- |
Market cap | 258.69m USD |
EPS (TTM) | -1.87 USD |
Data delayed at least 15 minutes, as of May 01 2024 21:00 BST.
More ▼